J

Johnson & Johnson

Makes prescription drugs and medical devices

Endpoint & AI Engineering Manager

Full-TimePosted on 10/22/2026Deadline 10/30/26
$117k - $201.3k+ Long-term incentive program
Expert
Bachelor's
Remote in USA
RemoteRemote work may be approved on a case-by-case basis.
IT OperationsSystem Administration

About the job

Requirements
  • A bachelor's degree or equivalent work experience is required.
  • At least 8 years of experience running enterprise IT services, technical products, or projects is required.
  • At least 4 years of experience managing macOS, iOS, and Android devices at enterprise scale using Microsoft Intune and Jamf is required.
  • Hands-on experience designing and deploying agentic AI workflows and automation using Copilot Studio, Power Automate, ServiceNow, or similar platforms is required.
  • Working knowledge of large language model concepts, including prompt engineering, retrieval-augmented generation, tool calling, and Model Context Protocol, is required.
  • Understanding of AI security and governance, including agent identity and permissions, data protection, and prompt injection risks in a regulated industry, is required.
  • Deep expertise in Microsoft Intune, Entra ID, single sign-on, and Conditional Access authentication flows is required.
  • Proficiency in Python and PowerShell scripting and Microsoft Graph API integration is required.
  • Experience with endpoint analytics, hardware and performance monitoring, and technology adoption reporting is required.
  • Experience creating technology roadmaps, solution architecture, and strategy documentation based on business needs is required.
  • Experience with agile or continuous engineering methods in a fast-paced environment is required.
  • Ability to lead change, partner with stakeholders, and deliver results is required.
  • Strong organization and prioritization skills, adaptability, and focus on outcomes in a multifaceted environment are required.
  • The role's technical areas include Conditional Access; Security Copilot and Copilot in Intune; Copilot Studio, Power Automate, and AI agent orchestration, including MCP; Intune App Protection Policies; Apple Business Manager and Automated Device Enrollment; app deployment, configuration profiles, and OS update management; Python, PowerShell, and Bash automation and scripting; and development-to-production release management across development, test, pilot, and production rings, including organizational change, communications, readiness, and support enablement.
Responsibilities
  • Lead the Generative AI and agentic AI strategy for Mac and mobile services, prioritizing use cases that reduce manual effort, improve employee experience, and strengthen security.
  • Design, build, and operate AI agents for proactive remediation, compliance drift detection, security response, and end-user self-service, with human-in-the-loop approvals and audit controls.
  • Drive adoption of AI capabilities in endpoint management, including Security Copilot and Copilot in Intune, and integrate agents using Copilot Studio, Power Automate, and Microsoft Graph.
  • Partner with AI governance, Information Security, Legal, and Privacy teams to ensure AI solutions meet responsible AI, data protection, and least-privilege requirements.
  • Measure and report the business value of AI solutions, including hours saved, time to resolution, ticket deflection, and compliance, and manage AI consumption costs.
  • Engineer modern management, provisioning, remote support, and security solutions for the company's onsite, hybrid, and remote workforce.
  • Centralize and automate wireless carrier data management to provide a consolidated view of employees with active wireless plans across multiple providers.
  • Lead the Jamf Pro to Microsoft Intune migration and the expansion of Mac as a Choice, including organizational change for users, support teams, and business partners.
  • Shape long-term Mac and mobile platform strategy, including AI-ready hardware selection for on-device versus cloud AI and lifecycle planning.
  • Lead endpoint discovery, separation, and integration for acquisitions and divestitures in line with timelines and regulatory requirements.
  • Use Databricks, Nexthink, Power BI, Microsoft Graph, and Generative AI-powered analytics to drive data-driven decisions.
  • Track vendor roadmaps and industry trends, especially evolving AI capabilities, and adjust plans as features change.
  • Maintain service architecture, standards, and documentation, and build AI fluency across the team through coaching and upskilling.
Desired Qualifications
  • Microsoft AI certifications or similar AI training are a plus.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.